GlaxoSmithKline (LON:GSK) had its price objective decreased by Liberum Capital from GBX 1,930 ($25.39) to GBX 1,840 ($24.20) in a research note released on Tuesday morning, Stock Target Advisor reports. Liberum Capital currently has a hold rating on the stock.

Several other analysts also recently issued reports on GSK. Morgan Stanley reissued a sell rating and issued a GBX 1,740 ($22.89) price target on shares of GlaxoSmithKline in a report on Tuesday, January 7th. Deutsche Bank set a GBX 1,600 ($21.05) price target on GlaxoSmithKline and gave the stock a neutral rating in a report on Monday, February 10th. DZ Bank raised their price target on GlaxoSmithKline from GBX 1,850 ($24.34) to GBX 2,000 ($26.31) and gave the stock a buy rating in a report on Thursday, October 31st. Shore Capital reissued a sell rating on shares of GlaxoSmithKline in a report on Wednesday, February 12th. Finally, Citigroup reissued a neutral rating on shares of GlaxoSmithKline in a report on Monday. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of GBX 1,846.87 ($24.29).

Shares of LON GSK opened at GBX 1,646.20 ($21.65) on Tuesday. The company has a market cap of $82.61 billion and a price-to-earnings ratio of 17.78. GlaxoSmithKline has a 12-month low of GBX 1,485.20 ($19.54) and a 12-month high of GBX 1,857 ($24.43). The company has a current ratio of 0.81, a quick ratio of 0.51 and a debt-to-equity ratio of 166.19. The stock’s 50 day simple moving average is GBX 1,769.45 and its 200 day simple moving average is GBX 1,726.12.

The firm also recently announced a dividend, which will be paid on Thursday, April 9th. Shareholders of record on Thursday, February 20th will be paid a dividend of GBX 23 ($0.30) per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a yield of 1.32%. This is an increase from GlaxoSmithKline’s previous dividend of $19.00. GlaxoSmithKline’s payout ratio is presently 0.99%.

In other GlaxoSmithKline news, insider Judy Lewent bought 788 shares of the business’s stock in a transaction on Wednesday, February 5th. The shares were purchased at an average price of GBX 2,344 ($30.83) per share, with a total value of £18,470.72 ($24,297.18). Also, insider Emma Walmsley sold 11,680 shares of GlaxoSmithKline stock in a transaction on Monday, February 17th. The shares were sold at an average price of GBX 1,661 ($21.85), for a total value of £194,004.80 ($255,202.32). Insiders have acquired a total of 810 shares of company stock worth $1,885,602 in the last ninety days.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Further Reading: Do You Need a Fiduciary?

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.